<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778956</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-CMY-2020-2302</org_study_id>
    <nct_id>NCT04778956</nct_id>
  </id_info>
  <brief_title>Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma: a Prospecitve, Parallel, Multicenter, Phase III, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan People's Hospital, Guangdong, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tenth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that&#xD;
      PD-1 treatment added to salvage surgery could further decrease the rate of disease&#xD;
      progression and improve the survival outcome of patients with resectable locally recurrent&#xD;
      nasopharyngeal carcinoma compared with those treated with salvage surgery alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Through multicenter, open-label, randomised clinical trials, patients with resectable locally&#xD;
      recurrent nasopharyngeal carcinoma are randomized into salvage surgery plus PD-1 treatment&#xD;
      group and salvage surgery alone group. The efficacy and safety of patients between these two&#xD;
      groups are compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">March 3, 2033</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from randomization to disease progression or death due to any cause, whichever come first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>3-5 weeks</time_frame>
    <description>Defined as the proportion of patients with radiologically confirmed complete or partial response according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Pathological Response Rate</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>Defined as the proportion of patients with no more than 10% viable tumor cells which is identified on routine hematoxylin and eosin staining within the recurrent nasopharyngeal tumor and/or regional lymph node after neoadjuvant PD-1 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from randomisation to the date of first distant metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from randomisation to the date of first locoregional relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) before treatment, during treatment, after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&amp;N35)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&amp;N35) before treatment, during treatment, after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>PD-1</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Toripalimab plus salvage surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab: Toripalimab treatment before and after salvage surgery.&#xD;
Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage surgery alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.</description>
    <arm_group_label>Toripalimab plus salvage surgery</arm_group_label>
    <other_name>PD-1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>salvage surgery</intervention_name>
    <description>Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.</description>
    <arm_group_label>Salvage surgery alone</arm_group_label>
    <arm_group_label>Toripalimab plus salvage surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The recurrence time is more than 6 months from the end of radiotherapy.&#xD;
&#xD;
          2. Histologically confirmed recurrent nasopharyngeal carcinoma.&#xD;
&#xD;
          3. Resectable nasopharyngeal diseases: recurrent T1 (the tumor is confined in&#xD;
             nasopharynx, oropharynx and/or nasal cavity without parapharyngeal involvement);&#xD;
             recurrent T2 (the tumor is confined in the superficial parapharyngeal spacer and is&#xD;
             more than 0.5cm far from the internal carotid artery) and recurrent T3 (the tumor is&#xD;
             confined in the base wall of the sphenoid sinus and is more than 0.5cm far from the&#xD;
             internal carotid artery and cavernous sinus). (according to the 8th edition of&#xD;
             American Joint Committee on Cancer (AJCC) staging system for nasopharyngeal carcinoma)&#xD;
&#xD;
          4. Resectable recurrent regional lymph node diseases (recurrent N1-3) without&#xD;
             prevertebral fascia, cervical vertebrae, or common/internal carotid artery&#xD;
             involvement. (according to the 8th edition of AJCC staging system)&#xD;
&#xD;
          5. Given written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Karnofsky Performance Status (KPS) ≤70.&#xD;
&#xD;
          2. Has severe medical disorder, important organ dysfunction, and/or a substantial history&#xD;
             of mental illness.&#xD;
&#xD;
          3. Has known subjects with other malignant tumors.&#xD;
&#xD;
          4. Has participated in other drug trials within 3 months of planned start of study&#xD;
             treatment.&#xD;
&#xD;
          5. Received a systematic or local glucocorticoid therapy within 4 weeks of planned start&#xD;
             of study treatment.&#xD;
&#xD;
          6. Suffered from diseases need long-term treatment with immunosuppressive drugs, or&#xD;
             required systematic or local glucocorticoid therapy with immunosuppressive doses.&#xD;
&#xD;
          7. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T&#xD;
             lymphocyte-associated antigen 4 (CTLA-4) agent.&#xD;
&#xD;
          8. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,&#xD;
             nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy).&#xD;
             Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo,&#xD;
             psoriasis, or alopecia) will be allowed to enroll.&#xD;
&#xD;
          9. Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface&#xD;
             antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml&#xD;
             or hepatitis C virus (HCV) antibody positive.&#xD;
&#xD;
         10. Has received a live vaccine within 4 weeks of planned start of study treatment.&#xD;
&#xD;
         11. Pregnancy or breast feeding.&#xD;
&#xD;
         12. Cannot complete regular follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <phone>86-20-87343624</phone>
    <email>chmingy@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>You-Ping Liu, MD, PhD</last_name>
    <phone>86-20-87343379</phone>
    <email>liuyoup@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <phone>86-20-8734-3624</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei-Ping Wen, MD, PhD</last_name>
      <phone>86-13802966937</phone>
      <email>wenwp@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao-Cheng Tang, MD.PhD</last_name>
      <phone>86-15920115552</phone>
      <email>hctang2006@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian-Zhong Zhang, MD</last_name>
      <phone>86-15820279737</phone>
      <email>525567166@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Tang, MD</last_name>
      <phone>86-18038860199</phone>
      <email>tjun@fsyyy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min-Yi Fu</last_name>
      <phone>86-13924933366</phone>
      <email>503498362@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tenth Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <phone>86-13903052650</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>Professor, Chief Doctor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Salvage surgery</keyword>
  <keyword>Anti-programmed death-1 antibody</keyword>
  <keyword>Disease free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

